CTNM

Contineum Therapeutics, Inc.

Healthcare
Biotechnology
$274M market cap

Forecast run · Oct 29, 2026Upside rank 653 of 3,186

Model Signal

ForecastQ Daily Probabilities

41.4%

51.5%

38.1%

Analyst Consensus

Recommendation2.50/5 Buy

Last price$8.31

Price target$21.33

Implied move+156.7%

Analysts4

ForecastQ Portfolios

CTNM is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.